Cerenis Therapeutics is specialized in research & development into HDL - Jean-Louis Dasseux, President and CEO of Cerenis Therapeutics 00:00:00
Cerenis Therapeutics is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases.
